Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02539550 | A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects | PHASE1 | COMPLETED | 25 | — | — | Aug 1, 2015 | May 1, 2016 | Jun 24, 2016 | 1 | Belgium |
Number of participants with AEs occurring after first dose of study drug. Relatedness to study drug will be assessed by investigator.
Number of subjects with standard safety laboratory test results of potential clinical significance (according to pre-defined criteria).
Absolute values and changes from baseline for the ECG parameters
Absolute values and changes from baseline for blood pressure and pulse rate
All abnormal rhythms will be reviewed by the study physician for the presence of rhythms of potential clinical concern. The time, duration and description of any clinically significant event will be recorded.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| PF-06266047 | EXPERIMENTAL | PF-06266047 |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo |
| PF-06266047 | DRUG | PF-06266047 |
Inclusion Criteria: 1. Healthy female subjects of non-childbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical exa...